Post-COVID-19 Hyposmia Does Not Exhibit Main Neurodegeneration Markers in the Olfactory Pathway.

Hyposmia Long-COVID Neurodegeneration Olfactory dysfunction Olfactory neurons Post-COVID

Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
04 Apr 2024
Historique:
received: 07 01 2024
accepted: 29 03 2024
medline: 4 4 2024
pubmed: 4 4 2024
entrez: 3 4 2024
Statut: aheadofprint

Résumé

The biological substrate of persistent post-COVID-19 hyposmia is still unclear. However, as many neurodegenerative diseases present with smell impairment at onset, it may theoretically reflect degeneration within the central olfactory circuits. However, no data still exist regarding the post-COVID-19 patients. As the olfactory neurons (ONs) mirror pathological changes in the brain, allowing for tracking the underlying molecular events, here, we performed a broad analysis of ONs from patients with persistent post-COVID-19 OD to identify traces of potential neurodegeneration. ONs were collected through the non-invasive brushing of the olfactory mucosa from ten patients with persistent post-COVID-19 hyposmia (lasting > 6 months after infection) and ten age/sex-matched controls. Immunofluorescence staining for protein quantification and RT-PCR for gene expression levels were combined to measure ONs markers of α-synuclein, amyloid-β, and tau pathology, axonal injury, and mitochondrial network. Patients and controls had similar ONs levels of oligomeric α-synuclein, amyloid-β peptide, tau protein, neurofilament light chain (NfL), cytochrome C oxidase subunit 3 (COX3), and the heat shock protein 60 (HSP60). Our findings thus did not provide evidence for synucleinopathy and amyloid-β mismetabolism or gross traces of neuronal injury and mitochondrial dysfunction within the olfactory system in the early phase of persistent post-COVID-19 hyposmia.

Identifiants

DOI: 10.1007/s12035-024-04157-w PMID: 38570429
pubmed: 38570429
doi: 10.1007/s12035-024-04157-w
pii: 10.1007/s12035-024-04157-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Sapienza Università di Roma
ID : SEED PNR (2021) "PROKINETICIN 2: a new potenzial neuroinflammatory biomarker in Alzheimer disease"
Organisme : Ministero dell'Università e della Ricerca
ID : DSB.AD006.371 "INVECCHIAMENTO ATTIVO E IN SALUTE (FOE 2022)

Informations de copyright

© 2024. The Author(s).

Références

Schirinzi T, Landi D, Liguori C (2020) COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol. https://doi.org/10.1007/s00415-020-10131-y
doi: 10.1007/s00415-020-10131-y pubmed: 32852580 pmcid: 7450256
Xu E, Xie Y, Al-Aly Z (2022) Long-term neurologic outcomes of COVID-19. Nat Med 28(11):2406–2415. https://doi.org/10.1038/s41591-022-02001-z
doi: 10.1038/s41591-022-02001-z pubmed: 36138154 pmcid: 9671811
Li C, Liu J, Lin J, Shang H (2022) COVID-19 and risk of neurodegenerative disorders: a mendelian randomization study. Transl Psychiatry 12(1):283. https://doi.org/10.1038/s41398-022-02052-3
Doty RL (2022) Olfactory dysfunction in COVID-19: pathology and long-term implications for brain health. Trends Mol Med 28:781–794. https://doi.org/10.1016/J.MOLMED.2022.06.005
doi: 10.1016/J.MOLMED.2022.06.005 pubmed: 35810128 pmcid: 9212891
Tan BKJ, Han R, Zhao JJ, Tan NKW, Quah ESH, Tan CJ, Chan YH, Teo NWY, Charn TC, See A, Xu S, Chapurin N, Chandra RK, Chowdhury N, Butowt R, von Bartheld CS, Kumar BN, Hopkins C, Toh ST (2022) Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ 378:e069503. https://doi.org/10.1136/bmj-2021-069503 . Erratum in: BMJ. 2022 Aug 9;378:o1939
Schirinzi T, Lattanzi R, Maftei D et al (2022) Substance P and prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction. Brain Behav Immun 108:302–308. https://doi.org/10.1016/J.BBI.2022.12.017
doi: 10.1016/J.BBI.2022.12.017 pubmed: 36549578 pmcid: 9760596
Esposito F, Cirillo M, De Micco R et al (2022) Olfactory loss and brain connectivity after COVID-19. Hum Brain Mapp 43:1548–1560. https://doi.org/10.1002/HBM.25741
doi: 10.1002/HBM.25741 pubmed: 35083823 pmcid: 8886650
Kovács T (2004) Mechanisms of olfactory dysfunction in aging and neurodegenerative disorders. Ageing Res Rev 3:215–232. https://doi.org/10.1016/j.arr.2003.10.003
doi: 10.1016/j.arr.2003.10.003 pubmed: 15177056
Kay LM (2022) Neuroscience of disease: COVID-19 and olfactory dysfunction: a looming wave of dementia? J Neurophysiol 128:436. https://doi.org/10.1152/JN.00255.2022
doi: 10.1152/JN.00255.2022 pubmed: 35894511 pmcid: 9377782
Brozzetti L, Sacchetto L, Cecchini MP, Avesani A, Perra D, Bongianni M, Portioli C, Scupoli M, Ghetti B, Monaco S, Buffelli M, Zanusso G (2020) Neurodegeneration-associated proteins in human olfactory neurons collected by nasal brushing. Front Neurosci 14:145. https://doi.org/10.3389/fnins.2020.00145
Schirinzi T, Maftei D, Passali FM et al (2022) Olfactory neuron prokineticin-2 as a potential target in Parkinson’s disease. Ann Neurol. https://doi.org/10.1002/ANA.26526
doi: 10.1002/ANA.26526 pubmed: 36218142
Borghammer P (2023) The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models. J Neural Transm 130:737–753. https://doi.org/10.1007/s00702-023-02633-66
Ubeda-Bañon I, Saiz-Sanchez D, Flores-Cuadrado A et al (2020) The human olfactory system in two proteinopathies: alzheimer’s and parkinson’s diseases. Transl Neurodegener 9:22. https://doi.org/10.1186/s40035-020-00200-7
Murphy C (2019) Olfactory and other sensory impairments in Alzheimer disease. Nat Rev Neurol 15:11–24. https://doi.org/10.1038/s41582-018-0097-5
doi: 10.1038/s41582-018-0097-5 pubmed: 30532084
Baghallab I, Reyes-Ruiz JM, Abulnaja K et al (2018) Epitomic characterization of the specificity of the anti-amyloid A monoclonal antibodies 6E10 and 4G8. J Alzheimer’s Dis 66:1235–1244. https://doi.org/10.3233/JAD-180582
doi: 10.3233/JAD-180582
Arnold SE, Lee EB, Moberg PJ et al (2010) Olfactory epithelium amyloid-β and PHFtau pathology in Alzheimer’s disease NIH public access. Ann Neurol 67:462–469. https://doi.org/10.1002/ana.21910
doi: 10.1002/ana.21910 pubmed: 20437581 pmcid: 2864948
Son G, Yoo SJ, Kang S et al (2021) Region-specific amyloid-β accumulation in the olfactory system influences olfactory sensory neuronal dysfunction in 5xFAD mice. Alz Res Therapy 13:4. https://doi.org/10.1186/s13195-020-00730-2
Attems J, Jellinger KA (2006) Olfactory tau pathology in Alzheimer disease and mild cognitive impairment. Clin Neuropathol 25:265–271
pubmed: 17140156
Abu-Rumeileh S, Abdelhak A, Foschi M et al (2023) The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain 146:421–437. https://doi.org/10.1093/BRAIN/AWAC328
doi: 10.1093/BRAIN/AWAC328 pubmed: 36083979
Soto IC, Fontanesi F, Liu J, Barrientos A (2012) Biogenesis and assembly of eukaryotic cytochrome c oxidase catalytic core. Biochim Biophys Acta 1817(6):883–897. https://doi.org/10.1016/j.bbabio.2011.09.005
Cheng MY, Hartl FU, Norwich AL (1990) The mitochondrial chaperonin hsp60 is required for its own assembly. Nature 348(6300):455–458. https://doi.org/10.1038/348455a0
doi: 10.1038/348455a0 pubmed: 1978929
Schirinzi T, Maftei D, Grillo P et al (2023) Olfactory neuron substance P is overexpressed in Parkinson’s disease reflecting gut dysfunction. Mov Disord. https://doi.org/10.1002/MDS.29433
doi: 10.1002/MDS.29433 pubmed: 37860930
Tirassa P, Schirinzi T, Raspa M et al (2021) What substance P might tell us about the prognosis and mechanism of Parkinson’s disease? Neurosci Biobehav Rev 131:899–911. https://doi.org/10.1016/J.NEUBIOREV.2021.10.008
doi: 10.1016/J.NEUBIOREV.2021.10.008 pubmed: 34653503
Schirinzi T, Maftei D, Ralli M et al (2021) Serum substance P is increased in Parkinson’s disease and correlates with motor impairment. Mov Disord. https://doi.org/10.1002/MDS.28824
doi: 10.1002/MDS.28824 pubmed: 34623702
Maftei D, Schirinzi T, Mercuri NB, Lattanzi R, Severini C (2022) Potential clinical role of prokineticin 2 (PK2) In: neurodegenerative diseases. Curr Neuropharmacol 20(11):2019–2023. https://doi.org/10.2174/1570159X20666220411084612
Schirinzi T, Maftei D, Pieri M, Bernardini S, Mercuri NB, Lattanzi R, Severini C (2021) Increase of prokineticin-2 in serum of patients with parkinson's disease. Mov Disord 36(4):1031–1033. https://doi.org/10.1002/mds.28458

Auteurs

Tommaso Schirinzi (T)

Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy. t.schirinzi@yahoo.com.

Daniela Maftei (D)

Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.

Riccardo Maurizi (R)

Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.

Maria Albanese (M)

Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.

Clara Simonetta (C)

Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.

Roberta Bovenzi (R)

Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.

Jacopo Bissacco (J)

Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.

Davide Mascioli (D)

Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.

Laura Boffa (L)

Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.

Maria Grazia Di Certo (MG)

Department of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.

Francesca Gabanella (F)

Department of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.

Beatrice Francavilla (B)

Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.

Stefano Di Girolamo (S)

Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.

Nicola Biagio Mercuri (NB)

Unit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.

Francesco Maria Passali (FM)

Unit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.

Roberta Lattanzi (R)

Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.

Cinzia Severini (C)

Department of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.

Classifications MeSH